The Dolaflexin-based Antibody–Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b-Reference-Cited by-同舟云学术

The Dolaflexin-based Antibody–Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b

Published:2021-03-15 Issue:5 Volume:20 Page:896-905
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Bodyak Natalya D.,Mosher Rebecca,Yurkovetskiy Aleksandr V.,Yin Mao,Bu Charlie,Conlon Patrick R.,Demady Damon R.,DeVit Michael J.,Gumerov Dmitry R.,Gurijala Venu R.,Lee Winnie,McGillicuddy Dennis,Park Peter U.,Poling Laura L.,Protopova Marina,Qin LiuLiang,Stevenson Cheri A.,Ter-Ovanesyan Elena,Uttard Alex,Xiao Dongmei,Xu Jian,Xu Ling,Bergstrom Donald A.,Lowinger Timothy B.

Funder

Mersana Therapeutics

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing Ovarian Cancer Therapeutics: The Role of Targeted Drug Delivery Systems;International Journal of Nanomedicine;2024-09

2. Inhibition of XPR1‐dependent phosphate efflux induces mitochondrial dysfunction: A potential molecular target therapy for hepatocellular carcinoma?;Molecular Carcinogenesis;2024-08-13

3. Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses;Nature Communications;2024-07-11

4. Sodium-dependent phosphate transporter NaPi2b as a candidate for targeted therapy: features of structure, function, and expression;Advances in Molecular Oncology;2024-06-28

5. Antibody drug conjugates in the clinic;Bioengineering & Translational Medicine;2024-05-04